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Inﬂammatory Articular Disease in Patients with Inﬂammatory
Bowel Disease: Result of the Swiss IBD Cohort Study
Saskia Ditisheim, MD,* Nicolas Fournier, PhD,† Pascal Juillerat, MD, MSc,‡ Valerie Pittet, PhD, MSc,†
Pierre Michetti, MD,§ Cem Gabay, MD,k and Axel Finckh, MDk on behalf of the Swiss IBD Cohort
Study Group
Background: Inﬂammatory bowel diseases (IBD) are systemic conditions that commonly display extraintestinal manifestations. Inﬂammatory articular
disease (IAD: axial or peripheral) is the most common extraintestinal manifestation. The aim of this study was to evaluate the prevalence and the clinical
characteristics associated with IAD in patients with IBD.
Methods: We analyzed patients enrolled in the Swiss IBD cohort study. IAD was deﬁned as persistent or recurrent joint pain with an inﬂammatory pattern
(night pain, progressive relief during the day, morning stiffness lasting at least 30 minutes) or the presence of arthritis as diagnosed by the physicians. A
multivariate logistic regression was performed to analyze which disease characteristics were independently associated with the presence of IAD.
Results: A total of 2353 patients with IBD, 1359 with Crohn’s disease, and 994 with ulcerative colitis (UC) were included. Forty-four percent of
patients fulﬁlled the criteria for IAD, whereas 14.5% presented with other extraintestinal manifestations. IAD was associated with Crohn’s disease, with
female sex, with older age, and generally in patients with more active intestinal disease. Only in UC, IAD was further associated with tobacco smoking
and with increasing body mass index.
Conclusions: This population of patients with IBD displays a high prevalence of IAD. IAD was more strongly associated with Crohn’s disease than
UC. Other risk factors for IAD were female sex, advanced age, active digestive disease, and tobacco consumption in patients with UC, which is
interesting given the established association between smoking and other inﬂammatory arthritides.
(Inﬂamm Bowel Dis 2015;21:2598–2604)
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M usculoskeletal disorders are well-recognized extraintestinalmanifestations (EIM) of inﬂammatory bowel diseases
(IBD). A similar etiopathogenesis has been postulated, based on
genetic and immunological data.1–4 The prevalence of inﬂammatory
articular disease (IAD) in patients with IBD has been reported
somewhere between 10% and 45%,5–7 reﬂecting possible differ-
ences in study design and patient selection.5,8–10 The pathogenic
link between articular involvement and IBD is not yet fully under-
stood. Some authors claim that the intestinal permeability may be
higher both in patients suffering from IBD11 and from spondyloar-
thropathies.12 Several studies have demonstrated minimal or
infraclinical digestive inﬂammation in patients with spondyloar-
thropathies or ankylosing spondylitis.13–16 Crohn’s disease (CD)
and spondyloarthropathies may be a similar immune-mediated
inﬂammatory disease with distinct phenotypes and different clini-
cal, immunological, histopathological, and genetic ﬁndings.3,16–18
Other common pathogenic pathways may involve the microbiome
and distinct set of adhesion molecules.19,20
The aim of this study was to investigate the prevalence of
IAD in a large multicentric cohort of well-characterized patients
with IBD living in Switzerland, and to identify disease
characteristics associated with the occurrence of IAD in patients
with IBD.
MATERIALS AND METHODS
This is a cross-sectional study, nested within a prospective
population-based cohort study of patients with IBD.
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Patients’ Population
The Swiss IBD Cohort Study was initiated by the IBDnet, an
interest group of the Swiss Society of Gastroenterology in
collaboration with the ﬁve Swiss University centers and funded by
the Swiss National Science Foundation since 2006 (www.ibdnet.ch).
All local ethics committees approved the study. The study is
described in detail elsewhere.21 Brieﬂy, patients were enrolled by
gastroenterologists in university hospitals, regional hospitals, and
private practices. Diagnosis of IBD was based on Lennard-Jones
criteria22 and was supported by endoscopic, radiological, or histo-
logical/surgical ﬁndings.21 To be included, a diagnosis of IBD had to
be established at least 4 months before the inclusion or the patients
must have had at least one recurrence of symptoms. It is estimated
that about 25% of all Swiss patients with IBD were enrolled up to
2013.23 The cohort appears to be representative of the Swiss IBD
population as the same likelihood to be enrolled in the cohort was
observed between regions.23
Patients included in the present analysis were adults
enrolled between July 2006 and December 2012. We excluded
patients who did not complete the questionnaire.
Two distinct questionnaires were used to collect information at
the time of patients’ inclusion: one was completed by the physician—
including disease characteristics and EIM—and one was completed
by the patients. The patient self-reported questionnaire contained a set
of questions on arthritides (see Questionnaire, Supplemental Digital
Content 1, http://links.lww.com/IBD/B21). To validate our articular
patient questionnaire, we administered the instrument to a control
population of patients coming for a screening colonoscopy. In this
group of 61 patients (mean age: 51.5 yrs, 59% male, 41% female),
67% reported some arthralgias, but only 13% fulﬁlled the criteria for
IAD. These results suggest that the patient questionnaire is able to
discriminate common arthralgias from IAD. As expected, the preva-
lence of self-reported arthralgias was fairly high in this elderly pop-
ulation. The “false-positive rate” of around 10% may be in part
explained by some inﬂammatory presentations of osteoarthritis and
by difﬁculties of some patients to qualify precisely their pain.
Outcome Variable
The outcome of interest for this analysis was the presence or
absence of IAD in patients with IBD. IAD associated with IBD
have been described and categorized using various criteria by
different medical specialists.5,24,25 Based on the clinical presenta-
tion, Orchard et al5 have proposed a classiﬁcation for peripheral
IAD manifestations in 1998, distinguishing a pauciarticular ﬂare-
linked manifestation (type 1) and a polyarticular chronic manifes-
tation (type 2). More recently, a consensus deﬁnition has proposed
to regroup the articular manifestations of a group of interrelated
conditions comprising ankylosing spondylitis, psoriasis, IBD, and
reactive arthritis into axial and peripheral articular disease.26,27
In this study, we deﬁned patients with IAD according to
either (1) having had a documented episode of arthritis, conﬁrmed
by the gastroenterologist who included the patient or (2) fulﬁlling
inﬂammatory pattern of pain on the patient questionnaire. An
inﬂammatory pattern of joint pain was assessed as persistent or
recurrent joint pain, associated with night pain, relief on movement,
and morning stiffness lasting at least 30 minutes, based on
published criteria.26–29 To assess the robustness of our IAD deﬁni-
tion, we performed a sensitivity analysis with a strict IAD deﬁnition
relying exclusively on the physician-reported IAD. We categorized
IAD in 2 subgroups: (1) pure peripheral articular disease and (2)
IAD with axial involvement, with or without peripheral arthritis.
Exposure Variable and Predictors
We extracted from the Swiss IBD Cohort Study database
demographic variables (age, sex), disease characteristics (symp-
tom duration, EIM, type of IBD, disease activity and extension,
familial history of IBD), treatment characteristics, lifestyle factors
(tobacco smoke, body mass index), and generic quality of life
measures (SF-36).
We used the Montreal classiﬁcation for localization of
intestinal disease at inclusion. In CD, L1 describes ileal disease,
L2 colonic involvement, L3 ileocolonic disease, and L4 isolated
upper gastrointestinal tract disease.30 For UC, we categorized the
condition into proctitis, left-sided colitis, and pancolitis. Severity
and activity of digestive disease was assessed by the gastroenter-
ologist according to the Crohn’s Disease Activity Index for pa-
tients with CD31 and the Modiﬁed Truelove and Witts Activity
Index32 for patients with UC. In CD, the cutoff for active disease
was set at Crohn’s Disease Activity Index $150,33 and for UC,
the cutoff for active disease was set at Modiﬁed Truelove and
Witts Activity Index $10.34 We used the WHO categorization
for the body mass index (BMI).
Statistical Analysis
The statistical analysis was performed using Stata v. 13.1
for Windows (StataCorp., College Station, TX). First, continuous
data distribution normality was assessed using normal Q–Q plots.
Normally distributed variables were presented as mean 6 SD,
whereas nonnormally distributed variables were presented as
median and interquartile range. Differences in mean values
between two groups were assessed by the Student’s t test for
normally distributed variables. For nonnormally distributed vari-
ables, the Wilcoxon–Mann–Whitney rank-sum test was used to
assess differences in distribution between two groups. Categorical
variables were presented as raw counts and relative percentages.
Differences in repartition of categorical variables among groups
were assessed using the chi-squared test, or the Fisher’s exact test
in case of insufﬁcient sample size. All statistical tests were two
sided, and the signiﬁcance level was set at 0.05. Confounding was
a concern in this study because it is known from the literature that
IAD is more often associated with CD, with other EIM of IBD
and longer disease durations.8,9,35,36 Because such differences may
produce spurious associations, we used multivariate adjustments
to overcome such confounding effects. We ﬁrst examined univar-
iate associations between disease characteristics and presence of
IAD using logistic regression. We then performed a multivariable
logistic regression to analyze which of the characteristics were
independently associated with the presence of IAD.
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RESULTS
A total of 2401 patients were included in the study. Patients
with indeterminate colitis (n ¼ 48) were excluded, leaving 2353
patients for the analysis (1359 patients with CD and 994 with
patients with UC). Forty-four percent of all patients fulﬁlled our
criteria for IAD, of which 42% presented a pure peripheral arthri-
tis. Only 29% of patients with IAD reported ever consulting
a rheumatologist for their symptoms (29% versus 7%, P ,
0.001). In two-thirds of cases, IAD was corroborated both by
patients and gastroenterologists. As expected, patients with IAD
were more often on nonsteroidal anti-inﬂammatory drugs than
patients without IAD (8% versus 3%, P , 0.001) and reported
lower quality of life (P , 0.001) (Table 1).
In univariate analyses, IAD was more frequent in patients
with CD than in patients with UC (64% versus 36%, P , 0.001).
Furthermore, IAD was more common in women than in men
(50% versus 37%, P , 0.001), in older than in younger patients
(mean age, 43 versus 38 yr, P , 0.001), and in smokers than in
TABLE 1. Baseline Characteristics of IBD Patients with and Without IAD
Patients’ Characteristics Patients with IAD (N ¼ 1036, 44%) Patients Without IAD (N ¼ 1317, 56%) P
Median age (IQR), yrs 43 (32.5–54) 38 (28–50) ,0.001
Gender: female (%) 56.2 43.8 ,0.001
Median BMI (IQR), kg/m2 23.5 (21.1–26.5) 23.0 (22.9–25.9) 0.006
Diagnosis
CD (%) 64.5 52.5
UC (%) 35.5 47.5 ,0.001
CD location
L1 (ileal) (%) 31.5 29.3
L2 (colonic) (%) 32.1 31.1
L3 (ileocolonic) (%) 35.5 38.6
L4 (upper gastrointestinal only) (%) 0.9 1.0 0.324
UC location
Proctitis (%) 15.1 16.3
Left-sided colitis (%) 46.1 39.7
Pancolitis (%) 38.8 44.0 0.148
Intestinal disease activity
CDAI .150 (%) 18.2 9.9 ,0.001
MTWSI $10 (%) 7.7 6.4 0.496
Median intestinal symptoms duration
(IQR; range), yrs
9 (4–18; 0–49) 7 (2–14; 0–49) ,0.001
Median articular symptoms duration
(IQR; range)
6 (2–13; 0–61) 4 (1–8.5; 0–57) ,0.001
Tobacco
Never smoked (%) 54.1 60.4
Past or current smoker (%) 45.9 39.6 0.002
EIM (%)a 20.8 9.6 ,0.001
Uveitis/iritis (%) 8.1 2.9 ,0.001
Erythema nodosum (%) 6.7 2.3 ,0.001
Pyoderma gangrenosum (%) 1.7 1.2 0.290
Aphthous ulcers/stomatitis (%) 9.3 2.7 ,0.001
Primary sclerosing cholangitis (%) 0.9 2.1 0.015
Quality of life SF-36 score
Physical (median, IQR) 46.2, 37.9–52.8 52.8, 45.3–56.6 ,0.001
Mental (median, IQR) 45.0, 33.8–52.2 49.1, 40.7–54.3 ,0.001
Seen by a rheumatologist (%) 29.2 7.4 ,0.001
Positive IBD history in family (%) 14.9 11.4 0.015
aEIM excluding IAD.
CDAI, Crohn’s Disease Activity Index; MTWSI, Modiﬁed Truelove and Witts Activity Index.
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nonsmokers (46% versus 36%, P , 0.001). Patients with IAD had
longer duration of intestinal symptoms than patients without articular
symptoms (9 versus 7 yr, P , 0.001), whereas no difference was
observed regarding the localization of intestinal disease, neither in
UC nor in CD. A slightly higher BMI was seen in patients with IAD
compared with patients without IAD (23.5 versus 23; P ¼ 0.006).
Patients with CD with active intestinal disease (Crohn’s Disease
Activity Index .150) had more often IAD (18% versus 10%, P
, 0.001), whereas there was no difference regarding disease activity
for patients with UC (Table 1). Patients with a positive family his-
tory of IBD were more frequently affected by IAD (15% versus
11%, P ¼ 0.02). Patients with IAD also presented more commonly
other EIM (21% versus 10%, P, 0.001). The most frequent EIM in
patients with IAD was oral aphthosis (9.3%), followed by uveitis
(8.1%) and erythema nodosum (6.7%). However, patients with
another EIM typically presented more IAD than patients with only
an intestinal disease (63% versus 41%).
Among the patients with IAD, peripheral arthritis was more
frequently associated with active disease in CD (23.3% versus
14.5%, P ¼ 0.007). Patients with peripheral IAD were also more
likely to have other EIM (24.2% versus 18.2%, P ¼ 0.019), in
particular erythema nodosum (P ¼ 0.026). No other patient char-
acteristic was associated with a speciﬁc type of IAD (peripheral
versus mixed; Table 2). Interestingly, 40.5% of all patients with
TABLE 2. Baseline Characteristics of IBD Patients with Pure Peripheral Versus Mixed IAD
Patients’ Characteristics Mixed, N ¼ 598 (57.7%) Pure Peripheral, N ¼ 438 (42.3%) P
Median age (median, IQR), yrs 43 (33–54) 42 (32–53) 0.239
Gender, female (%) 56.7 55.5 0.698
Median BMI (IQR), kg/m2 23.7 (21.1–26.7) 23.4 (21.0–26.5) 0.450
Diagnosis
CD (%) 63.6 65.8
UC (%) 36.4 34.2 0.463
CD location
L1 (ileal) (%) 34.1 28.0
L2 (colonic) (%) 27.6 38.0
L3 (ileocolonic) (%) 37.2 33.3
L4 (upper gastrointestinal only) (%) 1.1 0.7 0.064
UC location
Proctitis (%) 16.1 13.6
Left-sided colitis (%) 47.4 44.2
Pancolitis (%) 36.5 42.2 0.529
Intestinal disease activity
CDAI .150 (%) 14.5 23.3 0.007
MTWAI $10 (%) 37.1 8.5 0.635
Intestinal symptoms duration (median, IQR, range), yrs 9, 4–18, 0–49 9, 4–18, 0–46 0.879
Articular symptoms duration (median, IQR, range), yrs 7, 2–13, 0–60 6, 2–13, 0–61 0.076
Tobacco
Never smoked (%) 53.0 55.6
Past or current smoker (%) 47.0 44.4 0.403
EIM (%)a 18.2 24.2 0.019
Uveitis/iritis (%) 7.0 9.6 0.137
Erythema nodosum (%) 5.2 8.7 0.026
Pyoderma gangrenosum (%) 1.3 2.3 0.252
Aphthous ulcers/stomatitis (%) 8.5 10.3 0.343
Primary sclerosing cholangitis (%) 1.0 0.7 0.548
Quality of life SF-36 score
Physical (median, IQR) 45.5, 37.2–52.1 47.9, 40.1–53.8 0.002
Mental (median, IQR) 44.3, 33.7–51.7 45.8, 34.8–52.6 0.163
Seen by a rheumatologist (%) 30.1 27.5 0.410
aEIM excluding IAD.
CDAI, Crohn’s Disease Activity Index; MTWSI, Modiﬁed Truelove and Witts Activity Index.
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IAD experienced articular symptoms before onset of IBD symp-
toms. This occurred more frequently in patients with IAD with
mixed involvement than with pure peripheral IAD involvement
(45.6% versus 30.7%, P , 0.001). Approximately half of the
patients with IAD link their articular symptoms to their IBD
activity, in both subgroups (CD: 55.3% and UC: 46.7%).
Adjusting for all factors, the likelihood of presenting IAD
was signiﬁcantly higher in patients with CD compared with
patients with UC (odds ratio [OR]: 1.52, 95% conﬁdence interval
[CI]: 1.21–1.84; P , 0.001) (Table 3). Furthermore, females
appear to have approximately twice the risk of presenting an
IAD as males (CD—OR: 1.83, 95% CI: 1.41–2.38, P , 0.001;
UC—OR: 1.76, 95% CI: 1.29–2.41, P , 0.001). The risk of
presenting IAD was increasing with age (trend test, P , 0.001).
Tobacco consumption was not signiﬁcantly associated with IAD
in patients with CD, whereas patients with UC who smoke had
more frequently IAD (OR: 1.57, 95% CI: 1.01–2.24, P ¼ 0.013).
Increased BMI was also associated with IAD in patients with UC
(OR: 1.54 per increment of 10 kg/m2, 95% CI: 1.05–2.26, P ¼
0.03) but not in patients with CD. Patients with active intestinal
disease at the time of enrollment also tended to have more
frequently IAD (CD—OR: 2.5, 95% CI: 1.64–3.74; UC—OR:
1.54, 95% CI, 0.87–2.72). There was no independent risk for
IAD associated with the duration of IBD or with the localization
of the intestinal involvement, neither in CD nor in UC. Sensitivity
analysis with an alternative IAD deﬁnition restricted to physician-
reported arthritis revealed similar results (data not shown).
DISCUSSION
In this large cohort of patients with IBD, IAD was present
in 44% of patients, underscoring that articular involvement is
frequent in this population. IAD may sometimes be neglected by
specialists, as only one quarter (29%) of these patients reported
ever seeing a rheumatologist. Axial involvement was the most
common IAD presentation. IAD was more frequent in patients
with CD than with UC, in females and in elderly. In patients with
UC, IAD was further associated with smoking and overweight.
The prevalence of articular involvement reported in our
cohort is higher than described in some other studies5,6,8–10,37 but
is consistent with what Turkcapar et al7 described (46%). One
possible explanation for the high prevalence of IAD in this study
TABLE 3. Multivariate Logistic Regression of Clinical Parameters Associated with the Presence of IAD
Outcome: IAD versus No IAD
Patients with CD Patients with UC
OR 95% CI P OR 95% CI P
Age, yrs
,30 1 (ref) — — 1 (ref) — —
30–40 1.689 1.143–2.496 0.008 1.247 0.772–2.013 0.366
40–50 1.868 1.215–2.873 0.004 1.594 0.968–2.626 0.067
.50 2.321 1.479–3.645 ,0.001 1.665 0.991–2.799 0.054
Gender
Male 1 (ref) — — 1 (ref) — —
Female 1.832 1.385–2.424 ,0.001 1.733 1.257–2.389 0.001
Smoking status at diagnosis
Never smoked 1 (ref) — — 1 (ref) — —
Smoker 0.953 0.723–1.256 0.730 1.567 1.097–2.239 0.013
Disease duration since diagnosis (per 10 yrs) 0.923 0.783–1.089 0.343 1.204 0.996–1.456 0.055
BMI [per increment of 10 kg/m2] 1.004 0.722–1.395 0.980 1.538 1.049–2.255 0.027
Disease location (CD)
L1 1 (ref) — —
L2 0.972 0.686–1.378 0.875
L3 0.895 0.641–1.249 0.516
Disease location (UC)
Pancolitis 1 (ref) — —
Left-sided colitis 1.064 0.757–1.496 0.721
Proctitis 0.816 0.512–1.298 0.390
Disease activity at enrollment
Inactive 1 (ref) — — 1 (ref) — —
Activea 2.476 1.639–3.741 ,0.001 1.538 0.869–2.723 0.139
aCrohn’s Disease Activity Index $150 for CD and Modiﬁed Truelove and Witts Activity Index $10 for UC.
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might be relatively long disease duration in this cohort (median
duration of IBD: 8 yr, interquartile range: 3–16 yr). Veloso et al9
found that the prevalence of IAD doubles after 20 years of IBD,
whereas Palm et al8,10 described a 3-fold increase after 6 years of
disease. Another explanation for the high prevalence of IAD is the
preponderance of CD in the Swiss IBD cohort, whereas most
other cohorts included more patients with UC, typically less asso-
ciated with IAD.5,8,10 We considered IAD that occurred at any
time point during the course of the disease, as opposed to IAD
present only at inclusion,38 which could have further increased the
prevalence of articular manifestations. Finally, it is possible that
our deﬁnition of IAD overestimates the prevalence of IAD, as it
also includes patient-deﬁned articular symptoms, which may
overdiagnose IAD by up to 10%, based on our validation study.
In accordance with the literature,9,10,35 IAD occurs more
frequently in patients with CD than in patients with UC in our
cohort. We also found that IAD was signiﬁcantly more common
in patients with other EIM, such as cutaneous, ocular, or oral
complications.9,36 These ﬁndings corroborate the hypothesis of
similar pathways of the different EIM.20,39 Some authors have
also described an association between IAD and the localization
or the activity of the digestive disease.9,10,36 We did not ﬁnd any
association between the occurrence of IAD and the localization of
the intestinal involvement. Nevertheless, we could corroborate
a trend to more IADs in patients with more active digestive dis-
ease, in particular in patients with CD with pure peripheral arthri-
tis, as classically described.5 However, associations with disease
activity or speciﬁc therapies in a cross-sectional study design have
to be interpreted with caution, as the use of immunomodulatory
therapies may tend to weaken this association (bias towards the
null). In UC, tobacco consumption was a risk factor for IAD,
which is interesting given the established association between
smoking and other inﬂammatory arthritides such as rheumatoid
arthritis, ankylosing spondylitis, and systemic lupus erythemato-
sus.40–42 Similarly, higher BMI was associated with UC, which is
also an established risk factor for developing other articular dis-
eases, such as psoriatic arthritis or rheumatoid arthritis. Intrigu-
ingly, the association with tobacco was not found in patients with
CD, reproducing the differential effect of smoking on the intesti-
nal disease in UC and CD.43,44 Several mechanisms have been
proposed to explain the effect of tobacco, such as modulation of
cellular and humoral immunity, effect on gut permeability,
colonic mucus, and mucosal blood ﬂow. However, the precise
cellular and molecular mechanisms are still unknown.45–47
One important ﬁnding of our study is that only 29% of
patients having IAD ever consulted a rheumatologist for their
articular symptoms. Potentially, many of the IAD symptoms are
mild and self-limited and thus do not warrant specialized care.
However, one cannot exclude some trivialization of the articular
complaints by the treating physician confronted with patients with
chronic digestive symptoms. Patients with IBD and concomitant
IAD may warrant more aggressive therapy, suggesting that
physicians following patients with IBD should search for articular
manifestations, in particular if other EIM are present.
Strengths of this study are a large multicentric IBD cohort,
conﬁrmed by endoscopic and histological ﬁndings. Patients were
recruited from a wide variety of settings, such as private
practices, regional hospitals, and large tertiary centers. We do
not believe that selection bias played a major role in the
prevalence of IAD, as articular involvement was similar between
the different recruitment sources (P ¼ 0.78). The sensitivity
analysis restricted to physician-reported arthritis showed similar
results, suggesting that our results are not biased by patient-
reported articular involvement. Some methodological issues of
our study should be discussed. Our IAD deﬁnition included past
articular involvement and may be affected by recall bias. How-
ever, potential recall bias is unlikely to be differential between
the two groups, as all patients have IBD. Furthermore, we vali-
dated our patient questionnaire in a control population and dem-
onstrated a good discrimination between inﬂammatory articular
patterns and noninﬂammatory arthralgias. Our IAD deﬁnition
further relies on the diagnosis of arthritis by nonspecialists,
which is likely to result in underdiagnosis. In fact, in 35% of
our IAD cases, the physician was not aware of the articular
involvement. Furthermore, only one-third of these patients ever
reported seeing a rheumatologist for a formal diagnosis. How-
ever, we believe that by combining patient and physician-
reported articular involvement, we obtained a more reliable esti-
mate of IAD prevalence. Another common limitation of cohort
studies is missing data. In this cohort, the response rate to the
patient questionnaire was of 72%. We do not believe that miss-
ingness in this study was differential between patients with or
without IAD and is thus unlikely to bias our results in a signiﬁcant
way. We could not assess the temporality of IAD involvement in
relation to the course of the digestive disease, thus our results
represent a cumulated prevalence of IAD. Finally, anti-tumor
necrosis factor and immunomodulatory medications may have
inﬂuenced the presence of current IAD, as 20% of patients in
this analysis were on anti-tumor necrosis factor at inclusion.
However, our IAD deﬁnition included past arthritis episodes,
before immunomodulatory therapies; thus, current medication
is unlikely to have biased our overall IAD prevalence.
In conclusion, this study suggests that physicians need to
be aware of the various presentations of articular involvement
(axial, peripheral, mixed) to make an adequate diagnosis.
Gastroenterologists need to identify patients with IBD with
concomitant IAD, as these patients may probably need more
aggressive management and are more likely to suffer from other
extraintestinal complications.
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